中国医药(600056.SH)上半年净利降17.99%至6.88亿元
格隆汇8月27日丨中国医药(600056.SH)发布2019年半年度报告,实现营业收入168.60亿元,同比增长16.04%;归属于上市公司股东的净利润6.88亿元,同比减少17.99%;归属于上市公司股东的扣除非经常性损益的净利润6.64亿元,同比减少13.91%;基本每股收益0.6444元。
在国家医药产业政策持续改革、市场环境复杂多变的情况下,公司坚持“一体两翼”的发展战略,持续推进业务结构调整和业务转型,积极加大终端市场开发扩大纯销业务、加速区域网络布局,积极拓展国际市场业务,优化业务资源配置,加强业务模式转型创新,实现了营业收入的持续增长。报告期内,公司实现营业收入168.60亿元,同比增长16.04%。
报告期内,受“4+7带量采购”、“限抗”等政策因素叠加影响,公司主要工业产品阿托伐他汀钙及瑞舒伐他汀钙受到冲击,同时,原料药市场竞争进一步加剧,以及公司工业营销体系持续改革,公司医药工业板块营业收入同比有所下降,公司归属于上市公司股东的净利润同比下降17.99%,归属于上市公司股东的扣除非经常性损益的净利润同比下降13.91%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.